<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>personalized treatment intensification &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/personalized-treatment-intensification/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 27 Nov 2025 12:54:41 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>personalized treatment intensification &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Tailored Treatment Boost for Hormone-Sensitive Prostate Cancer</title>
		<link>https://bioengineer.org/tailored-treatment-boost-for-hormone-sensitive-prostate-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 27 Nov 2025 12:54:38 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[androgen receptor pathway inhibitors (ARPIs)]]></category>
		<category><![CDATA[Hormone-sensitive prostate cancer]]></category>
		<category><![CDATA[multimodal therapy survival outcomes]]></category>
		<category><![CDATA[personalized treatment intensification]]></category>
		<category><![CDATA[PSMA PET imaging]]></category>
		<guid isPermaLink="false">https://bioengineer.org/tailored-treatment-boost-for-hormone-sensitive-prostate-cancer/</guid>

					<description><![CDATA[In the evolving landscape of prostate cancer treatment, hormone-sensitive prostate cancer (HSPC) has traditionally been managed with androgen-deprivation therapy (ADT) as a monotherapy. For decades, ADT was the cornerstone of systemic therapy, exploiting the tumor’s dependence on androgens for growth and survival. However, recent advances in our understanding of the molecular and biological heterogeneity of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">302301</post-id>	</item>
	</channel>
</rss>
